<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Esophageal candidiasis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Esophageal candidiasis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Esophageal candidiasis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John W Baddley, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Candida</em> infections can involve mucous membranes (eg, oropharyngitis, esophagitis, and vulvovaginitis) or be focally or systemically invasive. The clinical manifestations, diagnosis, and treatment of esophageal candidiasis in adults will be reviewed here. Topic reviews that provide an overview of <em>Candida</em> infections, as well as those that discuss oropharyngeal candidiasis in adults and children, are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/2416.html" rel="external">"Overview of Candida infections"</a> and  <a class="medical medical_review" href="/d/html/2432.html" rel="external">"Oropharyngeal candidiasis in adults"</a> and  <a class="medical medical_review" href="/d/html/5972.html" rel="external">"Candida infections in children"</a> and  <a class="medical medical_review" href="/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The causative organism of esophageal candidiasis is almost always <em>C. albicans</em> although other species (<em>Candida glabrata</em> or <em>Candida krusei</em>) are occasionally identified [<a href="#rid1">1,2</a>].</p><p>Candidal esophagitis is typically seen in patients with human immunodeficiency virus (HIV) who have advanced immunosuppression (CD4 count &lt;100 cells/microL) [<a href="#rid2">2,3</a>]. It is also seen in patients who have hematologic malignancies, are hematopoietic cell transplant recipients, have solid organ cancer and are receiving cytotoxic chemotherapy, and, less commonly, those taking inhaled corticosteroids [<a href="#rid1">1,4</a>]. Invasive <em>Candida</em> infections can also be seen in patients with idiopathic CD4+ lymphocytopenia. (See  <a class="medical medical_review" href="/d/html/3726.html" rel="external">"Evaluation of the patient with HIV, odynophagia, and dysphagia"</a> and  <a class="medical medical_review" href="/d/html/3917.html" rel="external">"Idiopathic CD4+ lymphocytopenia"</a>.) </p><p class="headingAnchor" id="H2047564075"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The hallmark of esophageal candidiasis is pain on swallowing. Patients usually localize their pain to a discrete retrosternal area.</p><p>Patient with esophagitis often have evidence of oropharyngeal candidiasis (thrush) on exam; however, the absence of thrush does not preclude the diagnosis of esophagitis. Conversely, some patients with thrush may have asymptomatic esophagitis, as was demonstrated in a study of 22 patients with cancer, in which 10 patients had thrush and no symptoms of esophagitis, despite having evidence of esophagitis on endoscopy and positive cultures [<a href="#rid1">1</a>]. However, the clinical significance of these findings is unclear. </p><p>A more detailed discussion of the clinical manifestations of oropharyngeal disease is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/2432.html" rel="external">"Oropharyngeal candidiasis in adults", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of esophageal candidiasis should be considered in immunocompromised patients who present with odynophagia. (See  <a class="medical medical_review" href="/d/html/2241.html" rel="external">"Approach to the evaluation of dysphagia in adults"</a>.)</p><p>The diagnosis is usually made at endoscopy when white mucosal plaque-like lesions are noted  (<a class="graphic graphic_picture graphicRef83102" href="/d/graphic/83102.html" rel="external">picture 1</a>). Confirmatory biopsy shows the presence of yeasts and hyphae invading mucosal cells, and culture reveals <em>Candida</em>. </p><p>An alternative diagnostic approach in immunocompromised patients, particularly those with thrush, is to treat with oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> on the basis of the patient's history and physical exam findings. Odynophagia due to candidiasis should improve within several days. If symptoms do not improve after approximately 72 hours, endoscopy and biopsy should be performed since it is likely that a disease other than or in addition to <em>Candida</em> esophagitis is present [<a href="#rid2">2,5</a>]. </p><p>The differential diagnosis of esophageal candidiasis includes other infectious etiologies (eg, cytomegalovirus, herpes simplex virus), medication-induced esophagitis, and inflammatory conditions such as eosinophilic esophagitis [<a href="#rid6">6</a>]. The frequency of coinfection was illustrated in a study of 110 patients with HIV presenting with esophageal symptoms; among the 52 patients with <em>Candida</em> esophagitis, concomitant infection with cytomegalovirus was noted in 22 and with herpes simplex virus in 2 [<a href="#rid2">2</a>]. A more detailed discussion of the evaluation of odynophagia and dysphagia in patients with HIV is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3726.html" rel="external">"Evaluation of the patient with HIV, odynophagia, and dysphagia"</a>.)</p><p class="headingAnchor" id="H2681614066"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H1939098326"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Symptomatic patients with candidal esophagitis require antifungal therapy. (See <a class="local">'Regimens for nonpregnant adults'</a> below and <a class="local">'Treatment during pregnancy'</a> below.)</p><p>Sometimes, a patient may not have signs and symptoms of esophagitis but has <em>Candida</em> identified on esophageal brushings that were obtained during the evaluation of a different process. In this setting, the diagnosis (and the decision to treat) needs to be made on a case-by-case basis to determine if the findings are consistent with colonization or active disease. When making this decision, clinicians should take into account the patient's risk factors for esophagitis as well as the other findings noted on endoscopy. </p><p class="headingAnchor" id="H1937331430"><span class="h2">Regimens for nonpregnant adults</span></p><p class="headingAnchor" id="H979657569"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>Patients with candidal esophagitis should be treated with systemic antifungal therapy  (<a class="graphic graphic_table graphicRef86676" href="/d/graphic/86676.html" rel="external">table 1</a>) [<a href="#rid7">7</a>]; it should never be managed with topical agents [<a href="#rid5">5</a>]. The general duration of treatment is 14 to 21 days [<a href="#rid8">8</a>]. Intravenous therapy may be required initially in patients with severe disease who cannot take oral therapy. </p><p>For most patients, we suggest <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> due to its excellent efficacy, ease of administration, and low risk of toxicity [<a href="#rid8">8-11</a>]. We administer 400 mg orally or intravenously on day 1, then 200 to 400 mg daily. In a number of studies, the effectiveness of fluconazole therapy for treatment of candidal esophagitis has ranged from 80 to 90 percent [<a href="#rid5">5,12-17</a>]. <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> oral solution, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> oral suspension, <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>, echinocandins, and amphotericin B have been found to have comparable efficacy to fluconazole for initial treatment of esophageal candidiasis [<a href="#rid12">12-21</a>], but these agents are not usually used because they are associated with more side effects (amphotericin B and azoles), more drug-drug interactions (azoles), and an increased risk of relapse when standard doses are used (echinocandins) [<a href="#rid15">15-17,20</a>].</p><p>On rare occasion, a patient may have infection with a non-<em>albicans</em> species. When a patient has infection due to a fluconazole-resistant <em>C. glabrata</em>, an echinocandin is preferred because of cross-resistance among the azoles. By contrast, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> may be effective if <em>C. krusei</em> is the cause of esophagitis [<a href="#rid22">22</a>]. In patients with infection due to a non-<em>albicans</em> species, susceptibility testing of the isolate is important to help select the correct antifungal agent. (See  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p class="headingAnchor" id="H1838111485"><span class="h3">Patients whose esophagitis is refractory to fluconazole</span><span class="headingEndMark"> — </span>Some patients with documented candidal esophagitis do not respond to initial treatment with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>. This may be due to infection with a non-<em>albicans</em> species or emergence of drug resistance to fluconazole [<a href="#rid23">23-26</a>]. In patients with HIV, risk factors for developing resistance include advanced immunosuppression and chronic exposure to azoles [<a href="#rid26">26</a>].</p><p>For patients who were empirically treated with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> but had no response, endoscopy should be performed to obtain cultures and evaluate for an alternative etiology. (See <a class="local">'Diagnosis'</a> above.)</p><p>For patients with documented esophageal candidiasis due to <em>C. albicans</em> that is refractory to <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> after one week of treatment, we increase the dose of fluconazole (maximum of 800 mg fluconazole daily). If symptoms still persist after several days, repeat endoscopy should be performed to obtain cultures and sensitivity and to make sure that another disease is not causing the symptoms. If another condition is not found, a different antifungal agent should be administered, pending the results of the cultures; the choice of agent depends in part upon whether the patient is able to tolerate oral medications and the previously obtained antifungal susceptibility profile, if available  (<a class="graphic graphic_table graphicRef86676" href="/d/graphic/86676.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who can take oral therapy </strong>– For patients who can take oral therapy, we suggest oral <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> oral solution, or <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>  (<a class="graphic graphic_table graphicRef86676" href="/d/graphic/86676.html" rel="external">table 1</a>). There is no preferred therapy in this setting, and the choice of agent depends upon factors such as side effect profile and risk of drug interactions. Treatment should be modified pending the results of the culture; many times, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> resistance portends resistance to other azoles as well. Treatment should be continued for 28 days. </p><p></p><p class="bulletIndent1">Several studies have evaluated the use of these azoles for treatment of refractory esophageal candidiasis, and they appear to be effective in about 60 to 70 percent of patients [<a href="#rid19">19,27,28</a>]. As an example, in one study, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> oral suspension (400 mg twice daily) led to a clinical response in 32 of 43 patients (74 percent) with endoscopically documented esophageal candidiasis, which had been refractory to primary therapy with <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> or <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid28">28</a>]. The role of the extended-release posaconazole tablet in the treatment of esophageal candidiasis has not been studied. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who require intravenous therapy </strong>– In patients with refractory disease who require intravenous therapy (eg, those with severe disease), we typically initiate an echinocandin (<a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>, <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a>, or <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a>) rather than amphotericin B, which is more toxic. However, amphotericin B should be used for treatment of <em>Candida</em> infections that are resistant to echinocandins. Dosing recommendations are described in the table  (<a class="graphic graphic_table graphicRef86676" href="/d/graphic/86676.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1">When clinically improved, many patients are able to transition to an oral azole (based upon the culture results) to complete a 28-day course. </p><p></p><p class="bulletIndent1">The doses of echinocandins used for treatment of esophageal candidiasis are higher than those used for candidemia  (<a class="graphic graphic_table graphicRef86676" href="/d/graphic/86676.html" rel="external">table 1</a>). Although echinocandins have been found to be effective for the treatment of <em>Candida</em> esophagitis in several studies [<a href="#rid15">15-17,20,29-31</a>], there are higher rates of relapse when standard doses of echinocandins are compared with azoles [<a href="#rid15">15-17,20</a>]. However, when higher doses of <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> (150 mg daily) were used in a randomized trial comparing micafungin with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> 200 mg daily, outcomes were similar (85 and 89 percent of patients remained recurrence free four weeks post treatment in the micafungin and fluconazole arms, respectively) [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent1">Although most studies of echinocandins have looked at the treatment of initial disease, one study found that <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a> appears to be effective in the treatment of esophageal candidiasis resistant to <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid32">32</a>]. In this retrospective analysis of 17 patients with esophagitis who had resistant isolates or a refractory clinical infection (no improvement after one week of fluconazole therapy), caspofungin led to a favorable clinical response in the majority of patients with in vitro resistant isolates (11 of 14) and in those with clinically refractory disease (7 of 11). Follow-up studies to assess recurrence rates were not done. </p><p></p><p class="headingAnchor" id="H3651228352"><span class="h2">Treatment during pregnancy</span><span class="headingEndMark"> — </span>Amphotericin B is the treatment of choice for pregnant women with esophageal candidiasis during the first trimester [<a href="#rid33">33</a>]. Lipid formulations (3 to 4 mg/kg intravenously [IV] daily) are generally preferred. Although <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> is less studied than the deoxycholate formulation, the risk of toxicity is reduced. </p><p>Oral azoles are teratogenic and should <strong>not</strong> be used during the first trimester. After the first trimester, the decision must be individualized. Detailed information on the risks of using azoles during pregnancy is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Pregnancy'</a>.) </p><p>There are no human data regarding the use of echinocandins in pregnancy. </p><p class="headingAnchor" id="H833023097"><span class="h2">Adverse effects of therapy</span><span class="headingEndMark"> — </span>Azole therapy can be associated with gastrointestinal upset, and prolonged administration can cause hepatotoxicity. <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> is the only azole associated with visual disturbances, and it has a higher risk of rash, including photosensitivity, than other azoles. To assess for adverse events, we follow patients clinically and monitor aminotransferase for those who require prolonged treatment. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Adverse effects'</a>.)</p><p>For those taking <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, we also monitor trough levels to reduce the risk of toxicity. Therapeutic drug monitoring for other azoles is typically not warranted when short courses of therapy are administered. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Voriconazole'</a>.)</p><p>Echinocandins are very well tolerated but require IV administration. Drug interactions are uncommon because, unlike the azoles, these drugs are not metabolized via the cytochrome p450 pathway [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/13945.html" rel="external">"Pharmacology of echinocandins and other glucan synthesis inhibitors", section on 'Adverse effects'</a>.)</p><p>Amphotericin B is associated with a decline in glomerular filtration rate and electrolyte disturbances. (See  <a class="medical medical_review" href="/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H4218595249"><span class="h2">Suppressive therapy</span><span class="headingEndMark"> — </span>In immunocompromised patients with recurrent disease, we do not routinely use suppressive therapy because treatment of individual episodes with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> is effective and less likely to result in azole resistance [<a href="#rid35">35</a>].</p><p>However, for patients with multiple closely spaced episodes of esophageal candidiasis, providers may choose to initiate suppressive therapy to reduce the risk of recurrences [<a href="#rid35">35</a>]. We typically administer <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (100 to 200 mg orally), which can be administered daily or three times per week [<a href="#rid7">7,8</a>]; for most patients, we prefer once-daily dosing to reduce the risk of developing resistance. <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">Posaconazole</a> oral suspension (400 mg orally twice daily) is also an option but is generally reserved for those who prefer a liquid formulation and those who have disease that is refractory to fluconazole. </p><p>Suppressive therapy should be stopped when the underlying defect in cell-mediated immunity can be corrected (eg, when CD4 count is &gt;200 cells/microL or viral load is controlled in patients with HIV).</p><p class="headingAnchor" id="H670608801"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a>.)</p><p class="headingAnchor" id="H266239178"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15732.html" rel="external">"Patient education: Upper endoscopy (The Basics)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/1992.html" rel="external">"Patient education: Upper endoscopy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H6695891"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> − <em>Candida</em> species can be associated with infections involving mucosal membranes, including the esophagus. The majority of these infections are related to <em>Candida albicans</em>, although other species (<em>Candida glabrata</em> or <em>Candida krusei</em>) are occasionally identified. Candidal esophagitis is typically seen in immunocompromised patients, such as patients with HIV who have advanced immunosuppression, those who have hematologic malignancies or are hematopoietic cell transplant recipients, and those who have solid organ cancer and are receiving cytotoxic chemotherapy. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> − The hallmark of esophageal candidiasis is odynophagia or pain on swallowing. Patients with esophagitis often have evidence of oropharyngeal disease (thrush) on exam; however, the absence of thrush does not preclude the diagnosis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> − The diagnosis of <em>Candida</em> esophagitis is usually made through endoscopy with a biopsy of white mucosal plaque-like lesions. Histology demonstrates the presence of yeast and hyphae invading mucosal cells with a culture confirming <em>Candida</em>. An alternative diagnostic approach, particularly in immunocompromised patients with oropharyngeal candidiasis, is to treat with systemic antifungal agents on the basis of the patient's history. Odynophagia due to candidiasis should improve within several days. Endoscopy can be pursued if empiric therapy does not lead to symptom resolution. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> − Patients with symptomatic candidal esophagitis should be treated with systemic antifungal therapy  (<a class="graphic graphic_table graphicRef86676" href="/d/graphic/86676.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> − For most nonpregnant patients, we suggest initial therapy with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Although almost all systemic antifungal agents appear to be effective, we prefer fluconazole due to its ease of administration, lack of toxicity, reduced risk of drug interactions, and lower cost. However, on rare occasion, when a patient has infection due to <em>C. glabrata</em> or <em>C. krusei</em>, an alternative agent is required since fluconazole is typically not effective. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment during pregnancy</strong> − For pregnant patients, amphotericin B is the treatment of choice during the first trimester since oral azoles are teratogenic and should <strong>not</strong> be used. After the first trimester, the decision must be individualized. (See <a class="local">'Treatment during pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disease resistant to </strong><a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> − For patients with documented esophageal candidiasis due to <em>C. albicans</em> that is refractory to fluconazole after one week of treatment, we increase the dose of fluconazole (maximum dose 800 mg). If symptoms still persist after several days, then endoscopy should be performed to obtain repeat cultures and to make sure that another disease is not causing the symptoms. If another condition is not found, an alternative antifungal agent should be administered, pending the results of cultures  (<a class="graphic graphic_table graphicRef86676" href="/d/graphic/86676.html" rel="external">table 1</a>). Treatment for refractory disease is usually 28 days. (See <a class="local">'Patients whose esophagitis is refractory to fluconazole'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suppressive therapy</strong> − In immunocompromised patients with recurrent disease, we suggest<strong> not</strong> routinely using suppressive therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment of individual episodes with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> is effective and less likely to result in azole resistance. (See <a class="local">'Suppressive therapy'</a> above.) </p><p></p><p class="headingAnchor" id="H2438793948"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kieren Marr, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Samonis G, Skordilis P, Maraki S, et al. Oropharyngeal candidiasis as a marker for esophageal candidiasis in patients with cancer. Clin Infect Dis 1998; 27:283.</a></li><li><a class="nounderline abstract_t">Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med 1991; 151:1567.</a></li><li><a class="nounderline abstract_t">Wilcox CM, Straub RF, Clark WS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90:1938.</a></li><li><a class="nounderline abstract_t">Kanda N, Yasuba H, Takahashi T, et al. Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate. Am J Gastroenterol 2003; 98:2146.</a></li><li><a class="nounderline abstract_t">Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26:259.</a></li><li><a class="nounderline abstract_t">Geagea A, Cellier C. Scope of drug-induced, infectious and allergic esophageal injury. Curr Opin Gastroenterol 2008; 24:496.</a></li><li class="breakAll">Panel on guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV.  Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/candidiasis-0 (Accessed on March 27, 2023).</li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Klotz SA. Oropharyngeal candidiasis: a new treatment option. Clin Infect Dis 2006; 42:1187.</a></li><li><a class="nounderline abstract_t">Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.</a></li><li><a class="nounderline abstract_t">Lake DE, Kunzweiler J, Beer M, et al. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy 1996; 42:308.</a></li><li><a class="nounderline abstract_t">Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis 1995; 27:613.</a></li><li><a class="nounderline abstract_t">Wilcox CM, Darouiche RO, Laine L, et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176:227.</a></li><li><a class="nounderline abstract_t">Ally R, Schürmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33:1447.</a></li><li><a class="nounderline abstract_t">Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113:294.</a></li><li><a class="nounderline abstract_t">de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39:842.</a></li><li><a class="nounderline abstract_t">Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39:770.</a></li><li><a class="nounderline abstract_t">Barbaro G, Barbarini G, Calderon W, et al. Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis. Gastroenterology 1996; 111:1169.</a></li><li><a class="nounderline abstract_t">Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials 2000; 1:47.</a></li><li><a class="nounderline abstract_t">de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21:899.</a></li><li><a class="nounderline abstract_t">Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother 2015; 59:1671.</a></li><li><a class="nounderline abstract_t">Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997; 25:843.</a></li><li><a class="nounderline abstract_t">Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97:339.</a></li><li><a class="nounderline abstract_t">Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000; 30:749.</a></li><li><a class="nounderline abstract_t">Maenza JR, Merz WG, Romagnoli MJ, et al. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997; 24:28.</a></li><li><a class="nounderline abstract_t">Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:219.</a></li><li><a class="nounderline abstract_t">Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.</a></li><li><a class="nounderline abstract_t">Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44:607.</a></li><li><a class="nounderline abstract_t">Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33:1529.</a></li><li><a class="nounderline abstract_t">Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46:451.</a></li><li><a class="nounderline abstract_t">Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20:475.</a></li><li><a class="nounderline abstract_t">Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31:183.</a></li><li><a class="nounderline abstract_t">Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.</a></li><li><a class="nounderline abstract_t">Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42:1171.</a></li><li><a class="nounderline abstract_t">Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005; 41:1473.</a></li></ol></div><div id="topicVersionRevision">Topic 2427 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709877" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Oropharyngeal candidiasis as a marker for esophageal candidiasis in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1651690" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7484995" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14572559" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9502438" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18622166" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Scope of drug-induced, infectious and allergic esophageal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18622166" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Scope of drug-induced, infectious and allergic esophageal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575740" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oropharyngeal candidiasis: a new treatment option.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16983621" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804799" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8685642" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207371" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11577374" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12361815" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472817" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472806" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8898629" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11590489" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15801925" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25561337" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9356799" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7942935" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10816143" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8994752" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8537662" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715306" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Voriconazole treatment for less-common, emerging, or refractory fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243069" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11588698" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796357" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15298643" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12394797" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15841069" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575738" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Micafungin: a new echinocandin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16231260" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
